Investigational therapy gaining reputation as promising antiviral drug to fight COVID-19

(Houston Methodist) COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. The trial's criteria allows for the treatment of patients early in their clinical course and, in some cases, at times where they might have otherwise been intubated. Working with pharmaceutical company Gilead Sciences, Remdesivir's manufacturer and sponsor of the studies, Houston Methodist Hospital was the fifth site in the U.S. to join the clinical tri...